GlassScriptPhysician profile
Susan B Lipsy
NPI 1265525778
$3,851.69
in general payments reported to CMS, 2019-2025
29 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $878 · 2023: $1,179 · 2024: $548 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $427.67 | 2021-2024 | Myrbetriq, Veozah |
| 180 Medical, INC. | $378.54 | 2021-2024 | Gentlecath Glide, Gentlecath, Lofric |
| Coloplast Corp | $315.24 | 2023-2025 | Speedicath |
| Urovant Sciences INC | $273.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $220.58 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Urogen Pharma, INC. | $210.52 | 2021-2024 | Jelmyto |
| Dentsply Ih Ab | $206.27 | 2023-2025 | Lofric, Lofric |
| Abbvie INC. | $202.91 | 2021-2025 | |
| Antares Pharma, INC. | $176.43 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $160.18 | 2023-2025 | Jatenzo, Eligard |
| Dentsply Ih INC. | $140.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.33 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $120.61 | 2021-2023 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $105.40 | 2023 | Lynparza |
| Myovant Sciences INC. | $100.96 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $87.87 | 2023-2024 | Orgovyx, Gemtesa |
| Axonics, INC. | $73.11 | 2024 | Bulkamid |
| Olympus America INC. | $68.25 | 2023-2025 | Itind System |
| Tolmar Pharmaceuticals, INC. | $61.67 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $60.19 | 2024 | Provenge |
| Amgen INC. | $58.37 | 2021-2022 | |
| Clarus Therapeutics INC. | $55.65 | 2021 | |
| Janssen Biotech, INC. | $52.06 | 2025 | Erleada |
| Pfizer INC. | $48.99 | 2022-2023 | |
| Allergan, INC. | $33.03 | 2021 | |
| Immunitybio, INC. | $22.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.98 | 2025 | |
| Medtronic, INC. | $19.84 | 2025 | Altaviva |
| Accord Healthcare, INC. | $19.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Lipsy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.